MDS Pharma, Compendia Claim New Service Will Increase Efficiency, Lower Cost of PGx Profiling

According to MDS Pharma and Compendia, the OncoPreditor service can reduce the cost of genomic profiling experiments for a typical cancer drug from $1.5 million to $250,000.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.